Kizivat Tomislav, Maric Ivana, Mudri Dunja, Curcic Ines Bilic, Primorac Dragan, Smolic Martina
University of Osijek, Faculty of Medicine, Osijek, Croatia.
University Hospital Osijek, Osijek, Croatia.
J Clin Transl Hepatol. 2020 Sep 28;8(3):347-353. doi: 10.14218/JCTH.2020.00027. Epub 2020 Jul 21.
Nonalcoholic fatty liver disease (NAFLD) is a complex clinical entity which can be secondary to many other diseases including hypothyroidism, characterized by lowering of thyroid hormones and increased thyroid stimulating hormone (TSH). A lot of emerging data published recently advocates the hypothesis that hypothyroid induced NAFLD could be a separate clinical entity, even suggesting possible treatment options for NAFLD involving substitution therapy for hypothyroidism along with lifestyle modifications. In addition, a whole new field of research is focused on thyromimetics in NAFLD/NASH treatment, currently in phase 3 clinical trials. In this critical review we summarized epidemiological and pathophysiological evidence linking these two clinical entities and described specific treatment options with the accent on promising new agents in NAFLD treatment, specifically thyroid hormone receptor (THR) agonist and its metabolites.
非酒精性脂肪性肝病(NAFLD)是一种复杂的临床病症,它可能继发于许多其他疾病,包括甲状腺功能减退症,其特征是甲状腺激素水平降低和促甲状腺激素(TSH)升高。最近发表的许多新数据支持这样一种假说,即甲状腺功能减退引起的NAFLD可能是一个独立的临床实体,甚至还提出了针对NAFLD的可能治疗方案,包括甲状腺功能减退的替代疗法以及生活方式的改变。此外,一个全新的研究领域聚焦于甲状腺模拟物在NAFLD/NASH治疗中的应用,目前正处于3期临床试验阶段。在这篇批判性综述中,我们总结了将这两种临床实体联系起来的流行病学和病理生理学证据,并描述了具体的治疗方案,重点介绍了NAFLD治疗中前景广阔的新药物,特别是甲状腺激素受体(THR)激动剂及其代谢产物。